Stavudine
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Stavudine: From HIV Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Stavudine is an oral nucleoside reverse transcriptase inhibitor (NRTI) used in antiretroviral therapy for HIV. The TxGNN model predicts it may be effective for feline acquired immunodeficiency syndrome (FIV infection in cats). The only supporting evidence is 2 preclinical publications, both on stampidine, a stavudine derivative, and no clinical trials. This is a veterinary and animal-model question, not a new human indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV infection (SAHPRA registration records do not state an indication text) |
| Predicted New Indication | Feline acquired immunodeficiency syndrome |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Stavudine is a thymidine analogue NRTI. Drugs of this class block retroviral reverse transcriptase, the enzyme the virus needs to copy its genetic material.
Feline immunodeficiency virus (FIV) is a lentivirus, in the same broad family as HIV, and has a homologous reverse transcriptase. A drug that works against HIV could therefore plausibly act on FIV, which makes the prediction biologically reasonable.
The high TxGNN score (99.55%) mainly reflects how close HIV and FIV sit in the knowledge graph. It is not clinical evidence. Both retrieved papers studied stampidine, a stavudine aryl phosphoramidate derivative, not stavudine itself, so the evidence is indirect.
Two other predictions were also generated and do not change this assessment:
- Simian immunodeficiency virus (SIV) infection (score 99.55%). Only cell-culture and animal-model data exist. One macaque report (PMID 22013040) describes fatal pancreatitis in SIV-infected animals given a dideoxynucleoside regimen that included stavudine. This is consistent with stavudine’s known mitochondrial toxicity. SIV is a non-human animal-model infection, so it has little value as a repurposing target. Recommendation: Hold.
- A rare neurodevelopmental disorder with ataxic gait, absent speech and decreased cortical white matter (score 99.51%). This is a model prediction only, with no trials or literature and no evident mechanism. Stavudine’s neurotoxicity (peripheral neuropathy) argues against this use, especially in children. Recommendation: Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12654652 | 2003 | Preclinical in vivo study (stampidine, not stavudine) | Antimicrob Agents Chemother | In chronically FIV-infected cats, a single oral dose of 50 or 100 mg/kg gave a transient decrease of at least 1 log in FIV load in 5 of 6 cats, with no side effects. A 4-week twice-daily course was also tested. |
| 16570826 | 2006 | Preclinical PK/toxicity study (stampidine, not stavudine) | Arzneimittel-Forschung | In dogs and FIV-infected cats, oral dosing at 100 mg/kg (a non-toxic level) reached plasma concentrations 3-4 logs above the IC50. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| A40/20.2.8/0659 | Sonke-Laminevstav 30 | Tablet | Not stated in the registration record |
| 44/20.2.8/0212 | Tri-Nestlam 150/30/200 | Tablet | Not stated in the registration record |
Both products are oral tablets. The product names suggest multi-ingredient antiretroviral combinations, but this must be confirmed against the SAHPRA-approved Professional Information (PI).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
The Evidence Pack lists no drug interactions for stavudine. The literature and model rationale point to the known class of mitochondrial toxicities, including pancreatitis, lactic acidosis, peripheral neuropathy and lipodystrophy. These are relevant to any use in a new setting.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The evidence is limited to two preclinical veterinary studies of a derivative compound (stampidine), with no data on stavudine itself in FIV or SIV.
- Stavudine is already marketed for HIV in humans, so the predicted indications are animal-model or veterinary uses with little value as a human repurposing opportunity.
To proceed, the following is needed:
- Direct evidence on stavudine (not stampidine) in FIV or SIV models
- A clear decision on whether a veterinary or animal-model application is within scope
- The SAHPRA Professional Information (PI) for warnings and contraindications, which is needed before any safety screening
- Detailed mechanism of action data
- Justification for the toxicity profile (pancreatitis, neuropathy, mitochondrial toxicity) in any new target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.